Report : North America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disorder, Gastrointestinal Disorder, and Other), Procedure [Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), and Transarterial Chemoembolization (TACE)], and End User (Hospital & Clinic, Ambulatory Surgery Center, and Other End User)

At 8.8% CAGR, the North America Embolotherapy Market is speculated to be worth US$ 2,245.73 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the North America embolotherapy market was valued at US$ 1,354.02 million in 2022 and is expected to reach US$ 2,245.73 million by 2028, registering an annual growth rate of 8.8% from 2022 to 2028. Burgeoning incidence of cancer cases and boosting patient preference for minimally invasive procedures.                

The five most common types of cancer are breast, prostate, cervical, lung, and colorectal. However, of these five cancers, the leading cause of cancer-related death is lung cancer. Even though breast cancer has at least a 25% higher incidence among women, cervical carcinoma was the leading cause of death in 2020. According to National Cancer Registry (NCR), in 2020, ~110,000 new cases of cancer were diagnosed in South Africa, with over 56,000 cancer-related deaths, representing a quarter of premature noncommunicable disease-related mortality. This significant cancer burden is predicted to increase in the coming decades, with the incidence of new cases of cancer expected to rise to 138,000 and 175,000 by 2030 and 2040, respectively. Cancer-related mortality is predicted to rise to 73,000 and 94,000 during the same period. Moreover, according to the American Cancer Society journal, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Embolization is used to stop bleeding or block blood flow to a tumor or abnormal area of tissue. It is also used to treat liver and kidney cancer and neuroendocrine tumors. Embolizing agents, including embolic microspheres (beads), are used to restrict the vascular supply of tumors, and can be loaded with chemotherapeutic medicines, which elute and diffuse into the tissue. The vascular embolization device (previously the arterial embolization device) is intended to control hemorrhaging due to aneurysms, certain types of tumors, and arteriovenous malformations. The pipeline embolization device is used for the treatment of large and giant wide-neck intracranial aneurysms in the internal carotid artery. It helps prevent aneurysms and tumors from growing and causing harm to essential organs. Thus, the rising prevalence of cancer cases is creating a high demand for embolotherapy products.  

On the contrary, availability of other alternative therapies. 

  • Based on product, the North America embolotherapy market is segmented into embolic agents and support devices. The embolic agents segment held 84.5% market share in 2022, embolic agents US$ 1,054.36 million. It is projected to garner US$ 1,912.77 million by 2028 to expand at 8.9% CAGR during 2022–2028.
  • Based on Disease Indication, the North America embolotherapy market is categorized into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held 26.1% market share in 2022, amassing US$ 353.72 million. It is projected to garner US$ 615.05 million by 2028 to expand at 9.7% CAGR during 2022–2028.
  • Based on procedure, the North America embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization segment held 52.6% market share in 2022, amassing US$ 712.33 million. It is projected to garner US$ 1,206.45 million by 2028 to expand at 9.2% CAGR during 2022–2028.
  • Based on end user, the North America embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held 73.0% market share in 2022, amassing US$ 987.83 million. It is projected to garner US$ 1,648.45 million by 2028 to expand at 8.9% CAGR during 2022–2028.
  • Based on country, the North America embolotherapy market has been segmented into the US, Canada, and Mexico.  Our regional analysis states that the US captured 79.8% market share in 2022. It was assessed at US$ 1,080.92 million in 2022 and is likely to hit US$ 1,806.56 million by 2028, exhibiting a CAGR of 8.9% during the forecast period.  

Key players dominating the North America embolotherapy market are Abbott Laboratories; Boston Scientific Corporation; Cook Medical LLC; Johnson & Johnson; Medtronic; Acandis GmbH; Balt USA LLC; Stryker Corporation; Guerbet LLC; and Terumo Corporation among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure